HNGE · Hinge Health

The thesis

Hinge Health's shares are modestly more likely than not to beat the S&P 500 because the business keeps beating its own guidance. Third-quarter revenue rose 52% to $235.0 million, and 2026 revenue guidance rose to $879–881 million. The fourth-quarter report, expected in February 2027, settles the case. It has to show fourth-quarter revenue of at least $249 million and a first 2027 outlook that keeps growth intact.

The quarterly filing confirms the release. The company's Form 10-Q, filed on 9 November 2026, reports third-quarter revenue of $234.97 million against $154.21 million a year earlier. The 2 November 2026 results release reports a 33% non-GAAP operating margin, $77.2 million of non-GAAP operating income, $112.7 million of free cash flow and GAAP diluted earnings of $0.66 per share.

The price has now caught up with part of the beat. Adjusted daily closes show $114.32 on 30 October 2026, the last session before results, and $121.72 on 11 November 2026, with a 39.2% gain over three months. Finviz lists a consensus target of $135.38 in mid-November, so the market prices in the raised 2026 guide but leaves the 2027 outlook to be proven. The rating is Medium because the reported growth is strong and dated, while flat pricing and a 2027 margin target below today's level cap how much the February report can surprise.

Bullish and bearish views on Hinge Health, Inc.

The bull case on Hinge Health, Inc. (HNGE), in brief: revenue beat and guidance rose again. The bear case: prices per member stay flat.

Bull case

• Revenue beat and guidance rose again. Third-quarter revenue was $235.0 million against the company's $223–225 million guide, per the 2 November 2026 release. Fourth-quarter guidance of $249–251 million compares with a $239.026 million consensus estimate reported by Benzinga, and the 2026 range rose from $856–860 million.
• Enrollment drove the upside. Member enrollments rose almost 75% year over year and renewals almost 25%, management said on the 2 November 2026 call. Full-year yield, the share of covered lives that enrol as members, rose to 4.6% from 4.45%.
• Forward indicators are still growing quickly. Last-twelve-month calculated billings reached $960.3 million, up 54%, and clients reached 3,270, up 28%, as of 30 September 2026, per the company's 8-K.
• Cash generation funds buybacks. Chief Financial Officer James Budge said on the 2 November 2026 call that the company bought 296,000 shares for $26 million in the third quarter. Cash, equivalents, marketable securities and restricted cash were $358.5 million at 30 September 2026, per the release.
• New programs extend growth into 2027. About 9 million migraine lives across more than 800 clients mostly launch in the first quarter of 2027, management said on the 2 November 2026 call. Budge said migraine should add about 10–20 basis points of yield in 2027.
• Analysts keep raising or holding targets. On 3 November 2026, per Benzinga, Evercore ISI raised its target to $150 and Truist to $145, and Raymond James went to $138 from $92, as reported by CNBC. Stifel reaffirmed its bullish rating and $135 target on 10 November 2026, per Fiscal.ai.

Bear case

• Prices per member stay flat. Budge said on the 2 November 2026 call that the company expects roughly flat average selling prices in 2026 and again in 2027. Growth in 2027 has to come roughly equally from yield and from new covered lives.
• Gross margin may give some back. Non-GAAP gross margin was 88% in the third quarter, per the release. Management said on the call it will again target 85% in 2027 as it invests in the member experience.
• Share settlements and deals absorb cash. Budge cited $209 million of third-quarter outflows from acquisitions and net share settlement of employee stock awards on the 2 November 2026 call, far more than the $26 million spent on buybacks.
• Insiders sold into the October rally. SEC Form 4 filings show Budge sold 47,720 shares and director Gabriel Mecklenburg sold 200,000 shares on 12 October 2026, both at an average $103.13 under Rule 10b5-1 plans. Chief Executive Daniel Perez sold 4,100 shares at $100.20 on 6 October 2026.
• Commercial leadership changes during launches. Jim Pursley steps down as President on 1 January 2027, per the 8-K, the same quarter the bulk of migraine lives launch. Aaryn Pure takes over the commercial organization as Chief Commercial Officer.

Price setup

The shares closed at $121.72 on 11 November 2026, 3.7% below the 52-week intraday high of $126.40 set the same day. The close of $123.23 on 10 November 2026 and $122.19 on 9 November 2026 followed $115.76 on 6 November 2026, so the post-results advance came a week after the report rather than on it.

Adjusted daily closes put the 50-day moving average at $102.78 and the 200-day moving average at $70.14 as of 11 November 2026. The 52-week closing low was $31.17 on 6 February 2026. The mid-October insider sales printed near $103, close to the 50-day average, which marks the price range the October advance started from.

No earnings date falls before February 2027. Last year the company reported fourth-quarter results on 9 February 2026, per its release, so the next report is likely in the second week of February.

Catalysts ahead

• 1 January 2027: Jim Pursley steps down as President; Aaryn Pure leads the commercial organization as Chief Commercial Officer. The handover coincides with the first-quarter 2027 migraine launch, so it shows whether commercial execution stays on course.
• ~9 February 2027 (est.): Fourth-quarter 2026 report; the company reported the prior year's fourth quarter on 9 February 2026 and has not announced a date. Tests the $249–251M revenue guide and $81–83M non-GAAP operating income guide, and gives the 2027 contracted-lives count and the first 2027 outlook.

What would change the view

A weekly close below $105.14, the 13 October 2026 close that preceded the late-October advance. Fourth-quarter revenue under $249 million, or full-year 2026 revenue below $879 million, at the February 2027 report would also break the case.

The risks this note tracks, each with what would confirm it:

• Enrollment-driven growth slows as campaigns lap strong comparisons while average selling prices stay flat through 2027. Confirmed by: fourth-quarter revenue below $249M, or a sharp slowing from the almost 75% enrollment growth reported for the third quarter, at the February 2027 report.
• Insider and sponsor selling under scheduled plans outweighs the buying that followed the broker target raises. Confirmed by: new Form 4 open-market sales by Insight Venture Partners, executives or directors at a larger scale than the 247,720 shares sold on 12 October 2026.
• Migraine and gastrointestinal programs contribute later or less than the 2027 growth argument assumes. Confirmed by: migraine yield contribution below the 10–20 basis points management cited for 2027, or a delay to the summer 2027 gastrointestinal launch.
• Gross margin falls from 88% toward the 85% target management set for 2027, and acquisitions add further pressure. Confirmed by: a lower 2027 non-GAAP operating margin guide at the February 2027 report, or a large acquisition announced alongside one.
• The President's departure disrupts commercial execution during new-program launches. Confirmed by: client growth below the 28% reported at 30 September 2026, or further senior commercial departures after 1 January 2027.

What it trades with

The shares trade on company-specific results more than on the broad health-care sector. Hinge sells to employers and health plans, so demand tracks employer benefit budgets and plan spending on musculoskeletal care. The shares also behave like a high-growth software name and can move with growth-stock sentiment and interest-rate expectations. Scheduled insider and sponsor sales under Rule 10b5-1 plans add a stock-specific source of supply.